Trial Profile
Safety of ivacaftor in patients cystic fibrosis: An observational, post-approval study from US and UK cystic fibrosis registries
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 21 May 2018
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
- 21 May 2018 New trial record
- 10 May 2018 Results (n=9936) published in the Thorax.